nach oben

Die Nephrologie

Erschienen in:

02.01.2023 | Pflege | Leitthema

COVID-19 in der Intensivmedizin

verfasst von: Dr. med. Niklas Floß, Dr. med. Bastian Tebbe, PD Dr. med. Hana Rohn, Univ.-Prof. Dr. med. Oliver Witzke

Erschienen in: Die Nephrologie | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

COVID-19 („coronavirus disease 2019“) kann bei immunsupprimierten Patienten trotz der Verfügbarkeit von Impfstoffen und neuen antiviralen Medikamenten einen schweren Krankheitsverlauf nehmen, welcher häufig intensivmedizinisch versorgt werden muss. Einer der Hauptgründe dafür ist die allgemein schlechtere Immunreaktion unter Immunsuppression. Umso wichtiger ist es, die Stadien der Erkrankung zu kennen und die mittlerweile verfügbaren therapeutischen Optionen entsprechend auszuwählen.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, Coronavirus CNI, Research T (2020) A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733. https://doi.org/10.1056/NEJMoa2001017CrossRef

Merad M, Martin JC (2020) Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20(6):355–362. https://doi.org/10.1038/s41577-020-0331-4CrossRef

Mohlendick B, Schonfelder K, Zacher C, Elsner C, Rohn H, Konik MJ, Thummler L, Rebmann V, Lindemann M, Jockel KH, Siffert W (2022) The GNB3 c.825C〉T (rs5443) polymorphism and protection against fatal outcome of corona virus disease 2019 (COVID-19). Front Genet 13:960731. https://doi.org/10.3389/fgene.2022.960731CrossRef

Gao Y, Chen Y, Liu M, Shi S, Tian J (2020) Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. J Infect 81(2):e93–e95. https://doi.org/10.1016/j.jinf.2020.05.017CrossRef

Mulling N, Rohn H (2021) Angiotensin-converting enzyme 2 (ACE2): role in the pathogenesis of diseases outside of COVID-19. Nephrologe 16(3):185–188. https://doi.org/10.1007/s11560-021-00507-0CrossRef

Konik M, Lindemann M, Zettler M, Meller L, Dolff S, Rebmann V, Horn PA, Dittmer U, Krawczyk A, Schipper L, Trilling M, Anastasiou OE, Schwarzkopf S, Thummler L, Taube C, Schobel C, Brenner T, Skoda EM, Wilde B, Gackler A, Witzke O, Rohn H (2021) Long-term SARS-coV‑2 specific immunity is affected by the severity of initial COVID-19 and patient age. J Clin Med. https://doi.org/10.3390/jcm10194606CrossRef

Lindemann M, Krawczyk A, Dolff S, Konik M, Rohn H, Platte M, Thummler L, Schwarzkopf S, Schipper L, Bormann M, van de Sand L, Breyer M, Klump H, Knop D, Lenz V, Temme C, Dittmer U, Horn PA, Witzke O (2021) SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma. J Med Virol 93(5):3047–3054. https://doi.org/10.1002/jmv.26840CrossRef

Gackler A, Rohn H, Witzke O (2021) Acute renal failure in COVID-19. Nephrologe 16(2):66–70. https://doi.org/10.1007/s11560-020-00473-zCrossRef

Rohn H, Feldkamp T, Witzke O (2020) COVID-19 and the kidneys. Gastroenterologe 15(6):471–476. https://doi.org/10.1007/s11377-020-00484-1CrossRef

10.

Flythe JE, Assimon MM, Tugman MJ, Chang EH, Gupta S, Shah J, Sosa MA, Renaghan AD, Melamed ML, Wilson FP, Neyra JA, Rashidi A, Boyle SM, Anand S, Christov M, Thomas LF, Edmonston D, Leaf DE, Investigators S‑C (2021) Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am J Kidney Dis 77(2):190–203e1. https://doi.org/10.1053/j.ajkd.2020.09.003CrossRef

11.

Chung EYM, Palmer SC, Natale P, Krishnan A, Cooper TE, Saglimbene VM, Ruospo M, Au E, Jayanti S, Liang A, Deng JDJ, Chui J, Higgins GY, Tong A, Wong G, Teixeira-Pinto A, Hodson EM, Craig JC, Strippoli GFM (2021) Incidence and outcomes of COVID-19 in people with CKD: a systematic review and meta-analysis. Am J Kidney Dis 78(6):804–815. https://doi.org/10.1053/j.ajkd.2021.07.003CrossRef

12.

Rohn H, Feldkamp T, Witzke O (2020) COVID-19 and the kidneys. Nephrologe 15(4):210–215. https://doi.org/10.1007/s11560-020-00444-4CrossRef

13.

Robbins-Juarez SY, Qian L, King KL, Stevens JS, Husain SA, Radhakrishnan J, Mohan S (2020) Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis. Kidney Int 5(8):1149–1160. https://doi.org/10.1016/j.ekir.2020.06.013CrossRef

14.

Doevelaar AAN, Holzer B, Seibert FS, Bauer F, Stervbo U, Rohn BJ, Zgoura P, Schenker P, Vonbrunn E, Amann K, Viebahn R, Babel N, Westhoff TH (2020) Lessons for the clinical nephrologist: recurrence of nephrotic syndrome induced by SARS-CoV‑2. J Nephrol 33(6):1369–1372. https://doi.org/10.1007/s40620-020-00855-5CrossRef

15.

Puelles VG, Lutgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F, Lu S, Pfefferle S, Schroder AS, Edler C, Gross O, Glatzel M, Wichmann D, Wiech T, Kluge S, Pueschel K, Aepfelbacher M, Huber TB (2020) Multiorgan and renal tropism of SARS-coV‑2. N Engl J Med 383(6):590–592. https://doi.org/10.1056/NEJMc2011400CrossRef

16.

Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, Yi F, Yang HC, Fogo AB, Nie X, Zhang C (2020) Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 98(1):219–227. https://doi.org/10.1016/j.kint.2020.04.003CrossRef

17.

Westhoff TH, Seibert FS, Bauer F, Stervbo U, Anft M, Doevelaar AAN, Rohn BJ, Winnekendonk G, Dittmer U, Schenker P, Vonbrunn E, Amann K, Viebahn R, Babel N (2020) Allograft infiltration and meningoencephalitis by SARS-CoV‑2 in a pancreas-kidney transplant recipient. Am J Transplant 20(11):3216–3220. https://doi.org/10.1111/ajt.16223CrossRef

18.

van der Straten K, Guerra D, van Gils MJ, Bontjer I, Caniels TG, van Willigen HDG, Wynberg E, Poniman M, Burger JA, Bouhuijs JH, van Rijswijk J, Olijhoek W, Liesdek MH, Lavell AHA, Appelman B, Sikkens JJ, Bomers MK, Han AX, Nichols BE, Prins M, Vennema H, Reusken C, de Jong MD, de Bree GJ, Russell CA, Eggink D, Sanders RW (2022) Antigenic cartography using sera from sequence-confirmed SARS-CoV‑2 variants of concern infections reveals antigenic divergence of Omicron. Immunity 55(9):1725–1731.e4. https://doi.org/10.1016/j.immuni.2022.07.018CrossRef

19.

UKHSA UHSA (2021) SARS-CoV‑2 variants of concern and variants under investigation in England. Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV01 (B.1.1.529) UKHSA. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf. Zugegriffen: 31.12.2021

20.

Control ECfDPa (2022) Assessment of the further spread and potential impact of the SARS-CoV‑2 Omicron variant of concern in the EU/EEA, 19th update 2022. https://www.ecdc.europa.eu/sites/default/files/documents/RRA-19-update-27-jan-2022.pdf. Zugegriffen: 27.01.2022

21.

Ferguson NGA, Hinsley W, Volz E (2021) Report 50: Hospitalisation risk for Omicron cases in England 2021. https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf. Zugegriffen: 22.12.2021

22.

Agency EM (2022) First adapted COVID-19 booster vaccines recommended for approval in the EU. https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu. Zugegriffen: 01.09.2022

23.

Risk M, Hayek SS, Schiopu E, Yuan L, Shen C, Shi X, Freed G, Zhao L (2022) COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. Lancet Rheumatol. https://doi.org/10.1016/s2665-9913(22)00216-8CrossRef

24.

Paniskaki K, Konik MJ, Anft M, Meister TL, Marheinecke C, Pfaender S, Jager J, Krawczyk A, Zettler M, Dolff S, Westhoff TH, Rohn H, Stervbo U, Witzke O, Babel N (2022) Superior humoral immunity in vaccinated SARS-CoV‑2 convalescence as compared to SARS-COV‑2 infection or vaccination. Front Immunol 13:1031254. https://doi.org/10.3389/fimmu.2022.1031254CrossRef

25.

Paniskaki K, Anft M, Meister TL, Marheinecke C, Pfaender S, Skrzypczyk S, Seibert FS, Thieme CJ, Konik MJ, Dolff S, Anastasiou O, Holzer B, Dittmer U, Queren C, Fricke L, Rohn H, Westhoff TH, Witzke O, Stervbo U, Roch T, Babel N (2022) Immune response in moderate to critical breakthrough COVID-19 infection after mRNA vaccination. Front Immunol 13:816220. https://doi.org/10.3389/fimmu.2022.816220CrossRef

26.

Dolff S, Zhou B, Korth J, Luo D, Dai Y, Jahn M, Dorsch O, Anastasiou OE, Witzke O, Kribben A, Wilde B (2021) Evidence of cell-mediated immune response in kidney transplants with a negative mRNA vaccine antibody response. Kidney Int 100(2):479–480. https://doi.org/10.1016/j.kint.2021.05.013CrossRef

27.

Korth J, Jahn M, Dorsch O, Anastasiou OE, Sorge-Hadicke B, Eisenberger U, Gackler A, Dittmer U, Witzke O, Wilde B, Dolff S, Kribben A (2021) Impaired humoral response in renal transplant recipients to SARS-coV‑2 vaccination with BNT162b2 (Pfizer-bioNtech). Viruses. https://doi.org/10.3390/v13050756CrossRef

28.

Jahn M, Korth J, Dorsch O, Anastasiou OE, Sorge-Hadicke B, Tyczynski B, Gackler A, Witzke O, Dittmer U, Dolff S, Wilde B, Kribben A (2021) Humoral response to SARS-coV-2-vaccination with BNT162b2 (Pfizer-bioNtech) in patients on hemodialysis. Vaccines. https://doi.org/10.3390/vaccines9040360CrossRef

29.

Thummler L, Gackler A, Bormann M, Ciesek S, Widera M, Rohn H, Fisenkci N, Otte M, Alt M, Dittmer U, Horn PA, Witzke O, Krawczyk A, Lindemann M (2022) Cellular and humoral immunity against different SARS-coV‑2 variants is detectable but reduced in vaccinated kidney transplant patients. Vaccines (basel). https://doi.org/10.3390/vaccines10081348CrossRef

30.

Roch T, Rohn B, Blazquez-Navarro A, Meister TL, Blanco EV, Paniskaki K, Wellenkotter J, Zgoura P, Giglio T, Pfaender S, Stervbo U, Viebahn R, Cinkilic O, Westhoff TH, Babel N (2022) A vector-based vaccine dose after 3 doses of mRNA-based COVID-19 vaccination does not substantially improve humoral SARS-coV‑2 immunity in renal transplant recipients. Kidney Int Rep 7(4):932–934. https://doi.org/10.1016/j.ekir.2022.01.1068CrossRef

31.

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O’Connell AM, Simons D, Blomquist PB, Zaidi A, Nash S, Iwani Binti AAN, Thelwall S, Dabrera G, Myers R, Amirthalingam G, Gharbia S, Barrett JC, Elson R, Ladhani SN, Ferguson N, Zambon M, Campbell CNJ, Brown K, Hopkins S, Chand M, Ramsay M, Lopez Bernal J (2022) Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med 386(16):1532–1546. https://doi.org/10.1056/NEJMoa2119451CrossRef

32.

RKI FCd (2022) Hinweise zur Therapie und Versorgung von COVID-19. https://www.rki.de/DE/Content/Kommissionen/COVRIIN/Therapie_Versorgung/FG_COVRIIN_Therapie_Versorgung_node.html;jsessionid=04D97C7FBF9B5D1AABCDBD237F78147B.internet092. Zugegriffen: 01.12.2022

33.

Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J, Heller B, Morris J, Crystal C, Igbinadolor A, Huhn G, Cardona J, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Dabora MC, Klekotka P, Shen L, Skovronsky DM, Investigators B (2021) Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med 385(15):1382–1392. https://doi.org/10.1056/NEJMoa2102685CrossRef

34.

Group RC (2022) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399(10325):665–676. https://doi.org/10.1016/S0140-6736(22)00163-5CrossRef

35.

Thümmler L et al (2023) Early treatment with monoclonal antibodies or convalescent plasma reduces mortality in non-vaccinated COVID-19 high-risk patients. Viruses. https://doi.org/10.3390/v15010119CrossRef

36.

Prevention CfDCa (2022) The COVID-19 treatment guidelines panel’s statement on omicron subvariants and anti-SARS-coV‑2 monoclonal antibodies. https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-omicron-subvariants/. Zugegriffen: 05.12.2022

37.

Thummler L, Konik M, Lindemann M, Fisenkci N, Koldehoff M, Gackler A, Horn PA, Theodoropoulos F, Taube C, Zettler M, Anastasiou OE, Brass P, Jansen S, Witzke O, Rohn H, Krawczyk A (2022) Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment. Front Immunol 13:980698. https://doi.org/10.3389/fimmu.2022.980698CrossRef

38.

Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Loftis AJ, Alabanza P, Lipansky F, Painter WP (2021) Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv. https://doi.org/10.1101/2021.06.17.21258639CrossRef

39.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fatkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC (2020) Members A‑SG. Remdesivir for the treatment of Covid-19—final report. N Engl J Med 383(19):1813–1826. https://doi.org/10.1056/NEJMoa2007764CrossRef

40.

Arbel R, Sagy WY, Hoshen M, Battat E, Lavie G, Sergienko R, Friger M, Waxman JG, Dagan N, Balicer R, Ben-Shlomo Y, Peretz A, Yaron S, Serby D, Hammerman A, Netzer D (2022) Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge. N Engl J Med 387(9):790–798. https://doi.org/10.1056/NEJMoa2204919CrossRef

41.

Salerno DM, Jennings DL, Lange NW, Kovac DB, Shertel T, Chen JK, Hedvat J, Scheffert J, Brown RS Jr., Pereira MR (2022) Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. Am J Transplant 22(8):2083–2088. https://doi.org/10.1111/ajt.17027CrossRef

42.

Liverpool Uo (2022) Liverpool COVID-19 Drug Interactions. https://www.covid19-druginteractions.org/checker. Zugegriffen: 06.12.2022

43.

Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, Metzendorf MI, Stegemann M, Benstoem C, Fichtner F (2021) Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.Cd014962CrossRef

44.

Stancampiano F, Jhawar N, Alsafi W, Valery J, Harris DM, Kempaiah P, Shah S, Heckman MG, Siddiqui H, Libertin CR (2022) Use of remdesivir for COVID-19 pneumonia in patients with advanced kidney disease: a retrospective multicenter study. Clin Infect Pract 16:100207. https://doi.org/10.1016/j.clinpr.2022.100207CrossRef

45.

Guberina H, da Silva Nardi F, Michita RT, Dolff S, Bienholz A, Heinemann FM, Wilde B, Trilling M, Horn PA, Kribben A, Witzke O, Rebmann V (2018) Susceptibility of HLA-E*01:03 allele carriers to develop cytomegalovirus replication after living-donor kidney transplantation. J Infect Dis 217(12):1918–1922. https://doi.org/10.1093/infdis/jix638CrossRef

46.

Cherneha M, Korth J, Kaulfuss M, Trilling M, Widera M, Rohn H, Dolff S, Babel N, Hoerning A, Kribben A, Witzke O (2021) Reactivations of latent viral infections are associated with an increased Thr389 p70S6k phosphorylation in peripheral lymphocytes of renal transplant recipients. Viruses. https://doi.org/10.3390/v13030424CrossRef

47.

Korth J, Widera M, Dolff S, Guberina H, Bienholz A, Brinkhoff A, Anastasiou OE, Kribben A, Dittmer U, Verheyen J, Wilde B, Witzke O (2018) Impact of low-level BK polyomavirus viremia on intermediate-term renal allograft function. Transpl Infect Dis. https://doi.org/10.1111/tid.12817CrossRef

48.

Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384(8):693–704. https://doi.org/10.1056/NEJMoa2021436CrossRef

49.

Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K, Metzendorf MI, Fischer AL, Kopp M, Stegemann M, Skoetz N, Fichtner F (2021) Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.Cd014963CrossRef

50.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637–1645. eng. Declaration of interests The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry. https://doi.org/10.1016/s0140-6736(21)00676‑0. Cited in: Pubmed; PMID 33933206.

51.

Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW, Group C‑BS (2021) Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 9(12):1407–1418. https://doi.org/10.1016/S2213-2600(21)00331-3CrossRef

52.

Investigators R‑C, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettila V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG (2021) Interleukin‑6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 384(16):1491–1502. https://doi.org/10.1056/NEJMoa2100433CrossRef

53.

Olnes MJ, Kotliarov Y, Biancotto A, Cheung F, Chen J, Shi R, Zhou H, Wang E, Tsang JS, Nussenblatt R (2016) Effects of systemically administered hydrocortisone on the human Immunome. Sci Rep 6:23002. https://doi.org/10.1038/srep23002CrossRef

54.

Nassiri AA, Hakemi MS, Miri MM, Shahrami R, Koomleh AA, Sabaghian T (2021) Blood purification with CytoSorb in critically ill COVID-19 patients: a case series of 26 patients. Artif Organs 45(11):1338–1347. https://doi.org/10.1111/aor.14024 (The authors declare that they have no conflicts of interest with the contents of this article. Epub 20210706)CrossRef

55.

Stockmann H, Thelen P, Stroben F, Pigorsch M, Keller T, Krannich A, Spies C, Treskatsch S, Ocken M, Kunz JV, Krüger A, Khadzhynov D, Kron S, Budde K, Eckardt KU, Enghard P, Lehner LJ (2022) CytoSorb rescue for COVID-19 patients with vasoplegic shock and multiple organ failure: a prospective, open-label, randomized controlled pilot study. Crit Care Med 50(6):964–976. https://doi.org/10.1097/ccm.0000000000005493CrossRef

56.

Lameire N, Vanmassenhove J (2018) Timing of dialysis in sepsis and acute respiratory distress syndrome. Am J Respir Crit Care Med 198(1):4–5. https://doi.org/10.1164/rccm.201801-0129EDCrossRef

57.

Smith DM, Li JZ, Moser C, Yeh E, Currier JS, Chew KW, Hughes MD, Team A‑AS (2022) Recurrence of symptoms following a 2-day symptom free period in patients with COVID-19. JAMA Netw Open 5(10):e2238867. https://doi.org/10.1001/jamanetworkopen.2022.38867CrossRef

58.

Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R (2022) COVID-19 rebound after paxlovid and molnupiravir during january–June 2022. medRxiv. https://doi.org/10.1101/2022.06.21.22276724CrossRef

59.

Wunsch K, Anastasiou OE, Alt M, Brochhagen L, Cherneha M, Thummler L, van Baal L, Madel RJ, Lindemann M, Taube C, Witzke O, Rohn H, Krawczyk A, Jansen S (2022) COVID-19 in elderly, immunocompromised or diabetic patients-from immune monitoring to clinical management in the hospital. Viruses. https://doi.org/10.3390/v14040746CrossRef

60.

Camprubí D, Gaya A, Marcos MA, Martí-Soler H, Soriano A, Mosquera MDM, Oliver A, Santos M, Muñoz J, García-Vidal C (2021) Persistent replication of SARS-CoV‑2 in a severely immunocompromised patient treated with several courses of remdesivir. Int J Infect Dis 104:379–381. https://doi.org/10.1016/j.ijid.2020.12.050CrossRef

61.

Abbasi J (2021) Researchers tie severe immunosuppression to chronic COVID-19 and virus variants. JAMA 325(20):2033–2035. https://doi.org/10.1001/jama.2021.7212CrossRef

62.

Hogan JI, Duerr R, Dimartino D, Marier C, Hochman SE, Mehta S, Wang G, Heguy A (2022) Remdesivir resistance in transplant recipients with persistent COVID-19. Clin Infect Dis. https://doi.org/10.1093/cid/ciac769CrossRef

63.

Speichert LJ, Schweda A, Witzke O, Konik M, Rohn H, Stettner M, Musche V, Herchert K, Fink M, Geiger S, Bauerle A, Skoda EM, Teufel M, Dinse H (2022) Fear of death during COVID-19 does not explain post-infection depression symptoms beyond reported symptoms during the infection in COVID-19 survivors. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph192113773CrossRef

64.

Dinse H, Speichert LJ, Schweda A, Witzke O, Konik M, Zettler M, Rohn H, Stettner M, Musche V, Weismuller B, Herchert K, Fink M, Moradian S, Teufel M, Skoda EM, Bauerle A (2022) „Impact of COVID-19 on public mental health and the buffering effect of a sense of coherence“: high level of COVID-19-related posttraumatic stress in COVID-19 survivors with low sense of coherence. Psychother Psychosom 91(2):139–141. https://doi.org/10.1159/000520963 (Comment on Schafer et al)CrossRef

65.

Stephenson J (2022) Report on long COVID urges actions to address needs of patients, Caregivers. JAMA Health Forum 3(12):e225254. https://doi.org/10.1001/jamahealthforum.2022.5254CrossRef

66.

Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, Lekoubou A, Oh JS, Ericson JE, Ssentongo P, Chinchilli VM (2021) Short-term and long-term rates of postacute sequelae of SARS-coV‑2 infection: a systematic review. JAMA Netw Open 4(10):e2128568. https://doi.org/10.1001/jamanetworkopen.2021.28568 (Conflict of Interest Disclosures: Dr Ericson reported consulting for Allergan outside the submitted work. No other disclosures were reported)CrossRef

67.

Kuczborska K, Buda P, Ksiazyk J (2022) Long-COVID in immunocompromised children. Eur J Pediatr 181(9):3501–3509. https://doi.org/10.1007/s00431-022-04561-1CrossRef

Titel: COVID-19 in der Intensivmedizin
verfasst von: Dr. med. Niklas Floß
Dr. med. Bastian Tebbe
PD Dr. med. Hana Rohn
Univ.-Prof. Dr. med. Oliver Witzke
Publikationsdatum: 02.01.2023
Verlag: Springer Medizin
Schlagwörter: Pflege
COVID-19
SARS-CoV-2
Erschienen in: Die Nephrologie / Ausgabe 1/2023
Print ISSN: 2731-7463
Elektronische ISSN: 2731-7471
DOI: https://doi.org/10.1007/s11560-022-00623-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

COVID-19 in der Intensivmedizin

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Dialyseeinleitung

Kochsalz- vs. balancierte Lösung auf der Intensivstation

Elektrolytstörungen in der Intensivmedizin

Nierenersatztherapie

Hämoperfusion und Plasmapherese auf der Intensivstation

Intensivmedizin

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin